This opportunity has expired. It is therefore no longer possible to like or apply.
See similar opportunities insteadYour career starts on Magnet.me
Create a profile and receive smart job recommendations based on your liked jobs.
Description
AtriCure, Inc. provides innovative technologies for the treatment of Atrial Fibrillation (Afib) and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of long standing persistent Afib. Additionally, our AtriClip Left Atrial Appendage (LAA) Exclusion System products are the most widely used LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
POSITION SUMMARY:
The Service Supervisor EMEA will be responsible for on-site and workshop service activities, including, but not limited to, preventive- and corrective maintenance, upgrades and installations, and maintaining the hardware installed base. The Service Supervisor EMEA supervises the onsite and workshop Service Technicians in their daily activities and planning. Additional support to our field colleagues will be part of the responsibility for this role. This position is a hands-on, stand-alone, supervision on-site/workshop position. In other words a very wide role, which will include travelling to various locations, amongst which EMEA hospitals and EMEA distributors.
ESSENTIAL FUNCTIONS OF THE POSITION:
ADDITIONAL ESSENTIAL FUNCTIONS OF THE POSITION:
BASIC QUALIFICATIONS:
PREFERRED QUALIFICATIONS:
AtriCure is an Equal Employment Opportunity/Affirmative Action employer and provides Drug Free Workplaces. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national or ethnic origin, age, protected veteran status, status as an individual with disability, sexual orientation, gender identity or any other characteristic protected by federal, state, or local law(s).
Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 150,000 implanted to date.
Change language to: Dutch
This page is optimised for people from the Netherlands. View the version optimised for people from the UK.